| Followers | 240 |
| Posts | 15523 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Monday, September 25, 2017 6:28:36 PM
Im a lawyer in The Netherlands
Well... I'm a graphic artist in the US. So with that kind of qualification, I'd guess that makes me more right! Humph.
Anyhow... if it came across that I thought a PR and an 8-k meant the same thing, I didn't mean to imply that.
I agree with this statement...
A press release does not have the same legal value as an 8K sec filing, by far! An 8K sec filing As the SEC explains it: “the types of information required to be disclosed on Form 8-K are generally considered to be ‘material,’
But in NWBO speak... and 8-k is also a way for the company to answer a single shareholder question in a few sentences and get it out to all share holders (instead of just telling one) and avoid having it disseminated widely throughout the investment and biotech world when it was really meant to reach those shareholders watching every move they make, and interpreting every 8-k, slide and PR they write in every possible light.
And yes, it would be considered a material event that would require an 8-K at the least when withdrawing from a stock exchange like Nasdaq.
And the company can also use an 8-k to clarify something that really doesn't have to be released within a 4 day minimum, something that's not particularly material, but it could become material if the answer was given to one or a few, and was not made available to everyone.
This 8-K was used to clarify that they would not be speaking at SMi.
Hardly material.
However, there was obviously some concern as to whether they were speaking there or not so the company opted to tell share holders they were not speaking there, and to provide them with a reason as to why they weren't. And the reason seems to be a good one.
But you are welcome to disagree.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
